TY - JOUR T1 - Acceleration of regional, racial and gender disparities in drug overdoses across the United States driven by COVID-19 and fentanyl use JF - medRxiv DO - 10.1101/2022.06.22.22276766 SP - 2022.06.22.22276766 AU - Maria R. D’Orsogna AU - Lucas Böttcher AU - Tom Chou Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/22/2022.06.22.22276766.abstract N2 - Objectives To examine trends in drug overdose deaths by gender, race and geography in the United States during the period 2013-2020.Methods We used the final National Vital Statistics System multiple cause-of-death mortality files to extract crude rates by gender and race and to calculate the male-to-female ratios of crude rates between 2013 and 2020. We established 2013-2019 temporal trends for four major drug types: psychostimulants with addiction potential (T43.6, such as methamphetamines); heroin (T40.1); natural and semi-synthetic opioids (T40.2, such as those contained in prescription pain-killers); synthetic opioids (T40.4, such as fentanyl and its derivatives) through a quadratic regression and determined whether changes in the pandemic year 2020 were statistically significant. We also identified states, race and gender categories most impacted by drug overdoses.Results Nationwide, the year 2020 saw statistically significant increases in overdoses for all drug categories except heroin, surpassing predictions based on 2013-2019 trends. Crude rates for Blacks of both genders surpassed those for Whites for fentanyl and psychostimulants in 2018 creating a gap that widened through 2020. In some regions mortality among Whites decreased while overdose rates for Blacks kept rising. The largest 2020 mortality statistic is for Black males in the District of Columbia, with a record 134 overdoses per 100,000 due to fentanyl, 9.4 times more than the fatality rate among White males. Male overdose crude rates in 2020 remain larger than those of females for all drug categories except in Idaho, Utah and Arkansas where crude rates of overdoses by natural and semisynthetic opioids for females exceeded those of males.Public Health Implications Drug prevention, mitigation and no-harm strategies should include racial, geographical and gender-specific efforts, to better identify and serve at risk groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Army Research Office through Grant No. W911NF-18-1-0345, the NIH through Grant No. R01HL146552 (T.C.), and the NSF through Grant No. DMS-1814090 (M.R.D.). The funders had no role in the design and conduct of the study the collection, management, analysis, and interpretation of the data the preparation or review of the article or the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:n/aI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData and codes for plotting are available at this link: https://github.com/dorsogna/drugs https://github.com/dorsogna/drugs ER -